Catalyst Pharmaceuticals Inc (CPRX)
16.53
-0.19
(-1.14%)
USD |
NASDAQ |
Mar 30, 10:36
Key Stats
Price and Performance | |
---|---|
Market Cap | 1.746B |
52 Week High (Daily) | Upgrade |
52 Week Low (Daily) | Upgrade |
All-Time High (Daily) | Upgrade |
Year to Date Total Returns (Daily) | Upgrade |
1 Month Total Returns (Daily) | Upgrade |
1 Year Total Returns (Daily) | 106.2% |
Valuation | |
PE Ratio | 22.34 |
PE Ratio (Forward) | Upgrade |
PS Ratio | 8.580 |
Price to Book Value | 5.813 |
EV to EBITDA | Upgrade |
Dividend | |
---|---|
Dividend | -- |
Dividend Yield (Forward) | Upgrade |
Financials | |
Revenue (5 Year Growth) | Upgrade |
Revenue (Quarterly YoY Growth) | Upgrade |
EPS Diluted (5 Year Growth) | Upgrade |
EPS Diluted (Quarterly YoY Growth) | Upgrade |
Debt to Equity Ratio | 0.00 |
Return on Equity | Upgrade |
Return on Assets | Upgrade |
Risk | |
Beta (5Y) | Upgrade |
Max Drawdown (5Y) | 66.55% |
News
Headline
Wire
Time (ET)
Yahoo
03/27 07:12
Yahoo
03/22 09:55
MT Newswires
03/16 08:22
Events
DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
05/11/2023* | 08:30 EST | Earnings Call | Q1 2023 | -- | -- | -- | |
05/10/2023* | -- | Results | Q1 2023 | -- | 0.31 | -- | |
03/16/2023 | 08:30 EST | Earnings Call | Q4 2022 | -- | -- | -- | |
03/15/2023 | -- | Results | Q4 2022 | 0.22 | 0.20 | 11.86% | |
11/10/2022 | 08:30 EST | Earnings Call | Q3 2022 | -- | -- | -- | |
11/09/2022 | -- | Results | Q3 2022 | 0.24 | 0.19 | 23.77% | |
08/10/2022 | 08:30 EST | Earnings Call | Q2 2022 | -- | -- | -- | |
08/09/2022 | -- | Results | Q2 2022 | 0.20 | 0.17 | 21.21% |
*Estimated Date/Time
Earnings
Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
URL | https://www.catalystpharma.com |
Investor Relations URL | https://ir.catalystpharma.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2023 (est.) |
Last Earnings Release | Mar. 15, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Dividends
Dividend Per Share (TTM) | -- |
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
Yield to Market | 0.00 |
Yield to Sector | 0.00 |
Yield to Industry | 0.00 |
Last Dividend Amt. | -- |
Dividend Frequency | -- |
Last Ex-Dividend Date | -- |
Yield (TTM) | 0% |
Forward Yield | -- |
Payout Ratio | 0.00% |
Cash Payout Ratio | 0.00% |
Consistent Payer (5Y) | No |
Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 29, 2023.
Fundamentals
Revenue (TTM) | 214.20M |
Total Expenses (TTM) | 112.36M |
Net Income (TTM) | 83.08M |
Total Assets (Quarterly) | 375.63M |
Total Liabilities (Quarterly) | 75.21M |
Shareholders Equity (Quarterly) | 300.42M |
Cash from Operations (TTM) | 116.05M |
Cash from Investing (TTM) | 9.209M |
Cash from Financing (TTM) | 1.694M |
Ratings
Profile
Catalyst Pharmaceuticals Inc is a biopharmaceutical company. It focuses on developing and commercializing innovative therapies for people with rare, debilitating, chronic neuromuscular and neurological diseases. It offers Firdapse, a proprietary form of amifampridine phosphate for the treatment of patients with Lambert-Eaton myasthenic syndrome. |
URL | https://www.catalystpharma.com |
Investor Relations URL | https://ir.catalystpharma.com/ |
HQ State/Province | Florida |
Sector | Healthcare |
Industry | Biotechnology |
Equity Style | Small Cap/Blend |
Next Earnings Release | May. 10, 2023 (est.) |
Last Earnings Release | Mar. 15, 2023 |
Next Ex-Dividend Date | N/A |
Last Ex-Dividend Date | N/A |
Ownership
Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
Consensus Rating
|
|
Analyst Recommendation
|
Source: S&P Global
Top Fund Holders
Symbol | Dollars Invested | % Weight |
---|---|---|
TGFRX | 1.360M USD | 8.79% |
PBE | 7.558M USD | 3.06% |
YOVAX | 763000.0 USD | 2.11% |
PTH | 3.522M USD | 1.95% |
PSCH | 4.678M USD | 1.63% |
BPLEX | 921059.0 USD | 1.30% |
XBI | 71.56M USD | 1.11% |
HIL269 | 4.862M USD | 1.09% |
IMPAX | 829541.0 USD | 1.03% |
DWAS | 4.597M USD | 0.92% |
QSMNX | 1.053M USD | 0.91% |
LABU | 7.444M USD | 0.85% |
Other Resources
Whale Wisdom | 13F Filings |
Seeking Alpha | Call Transcripts |
Nasdaq | Insider Trading |
Nasdaq | Institutional Ownership |
Nasdaq | Option Chain |
SEC | SEC Filings |
CPRX Tweets |